UCLA's PP405 shows promise in reactivating dormant hair follicles for hair loss treatment but is still in clinical trials. Minoxidil and finasteride remain common treatments until PP405 becomes available.
Someone switched from topical minoxidil to oral minoxidil and found it more effective and convenient, reporting improvements in hair, eyebrows, eyelashes, and beard without scalp issues. They are seeking long-term experiences from others who made the same switch.
Scientists at UCLA have developed a promising treatment for male pattern baldness using a molecule called PP405, which can potentially stimulate dormant hair follicles. Initial trials showed significant results within a week, but larger clinical trials are needed to confirm its efficacy and safety.
PP405 is a promising new hair loss treatment that may reactivate dormant hair follicles without side effects. It could surpass traditional treatments like minoxidil and finasteride if successful in further trials.
A person in their early 30s has been using finasteride for about 10 years and recently started oral minoxidil, vitamin chewables, and dermarolling to address hair loss. They noticed pigmented vellus hairs and potential regrowth, questioning if oral minoxidil is more effective than topical due to enzyme differences.